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creativecommons.org/licenses/by/4.0Summary Background: Brucella spp. prosthetic joint infections are infrequently reported in
the literature, particularly in returning travellers, and optimal treatment is unknown.
Method: We describe a prosthetic joint infection (PJI) caused by Brucella melitensis in a trav-
eller returning to the UK from Thailand, which we believe to be the first detailed report of
brucellosis in a traveller returning from this area. The 23 patients with Brucella-related PJI
reported in the literature are summarised, together with our case.
Results: The diagnosis of Brucella-related PJI is difficult to make; only 30% of blood cultures
and 75% of joint aspiration cultures were positive in the reported cases. Culture of intraopera-
tive samples provides the best diagnostic yield. In the absence of radiological evidence of joint
loosening, combination antimicrobial therapy alone may be appropriate treatment in the first
instance; this was successful in 6/7 [86%] of patients, though small numbers of patients and the
likelihood of reporting bias warrant caution in drawing any firm conclusions about optimal
treatment. Aerosolisation of synovial fluid during joint aspiration procedures and nosocomial
infection has been described.Trust Liverpool Glasgow Centre for Global Health Research, Block E Royal Infirmary Complex, 70
UK.
pool.ac.uk (J.M. Lewis).
16.08.010
ublished by Elsevier Ltd. This is an open access article under the CC BY license (http://
/).
Brucella prosthetic joint infection 445Conclusions: Brucella-related PJI should be considered in the differential of travellers return-
ing from endemic areas with PJI, including Thailand. Personal protective equipment including
fit tested filtering face piece-3 (FFP3) mask or equivalent is recommended for personnel car-
rying out joint aspiration when brucellosis is suspected. Travellers can reduce the risk of
brucellosis by avoiding unpasteurised dairy products and animal contact (particularly on farms
and abattoirs) in endemic areas and should be counselled regarding these risks as part of their
pre-travel assessment.
ª 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Brucellosis is a zoonotic infection transmitted to humans
from fluids of infected animals or through consumption of
unpasteurised dairy products [1]. It is caused by Brucella
spp., intracellular Gram-negative coccobacilli. Four species
cause most cases of human disease, each with a different
animal host reservoir: Brucella melitensis (goats, camels) is
most common, followed by Brucella abortus (cattle), Bru-
cella suis (pigs) and Brucella canis (dogs). Infections with
new species such a Brucella pinnepedialis and Brucella ceti
(marine animals) are occasionally recognized [2]. It can
cause an acute febrile illness after a usual incubation period
of 1e4 weeks, ranging up to 6 months, or chronic infection,
which can be without focus or can affect any organ system.
Osteoarticular involvement is the most common focal pre-
sentation. Diagnosis is usually based on serology, augmented
when possible by culture of Brucella organisms from blood,
synovial fluid, or bone. Promising molecular methods are in
development. Treatment is usually with combination ther-
apy of doxycycline, rifampicin  an aminoglycoside for
6e12 weeks [1]. Prosthetic joint infections (PJI) caused by
Brucella spp. are uncommonly reported in the literature.
We describe a PJI caused by B. melitensis in a traveller
returning to the UK from Thailand, the first detailed report
of brucellosis in a traveller returning from this area; we also
present a review of the 24 reported cases of Brucella-
related PJI in the literature.
2. Materials and methods
2.1. Case report
A 51-year old UK resident attended our clinic on 5 May 2015
with a 21-day history of daily rigors, profuse sweating at-
tacks and high fever. He had returned from Thailand three
months earlier. He also had pain and swelling in his left
knee, in which he had an uncomplicated total knee
replacement 5 years previously for early onset osteoarthritis
following trauma. The only abnormalities on examination
were fever of 38.3 C and a small effusion in the symptom-
atic knee. Blood cultures yielded Gram-negative coccobacilli
after 3 days (BioMerieux Bact/ALERT blood culture system),
identified as B. melitensis by matrix-assisted laser desorp-
tion/ionization time-of-flight (MALDI-TOF) mass spectrom-
etry (Bruker microflex LT), but not before two laboratory
scientists had been exposed to open bacterial culture plates.The organism was confirmed as B. melitensis biotype 3 in the
Veterinary Investigation Centre in Weybridge. Standard
agglutination tests for brucellosis were suggestive of chronic
infection, with IgG titres of >1:2560 and IgM 1:80.
Aspiration of the knee was carried out by the orthopaedic
team, equipped with personal protective equipment [PPE]
consisting of gown, gloves, apron, visor and filtering face
piece-3 [FFP3] respirator. Cloudy fluid was aspirated; this
contained over 6000 lymphocytes/mm3 and cultured B.
melitensis after 7 days. The patient commenced doxycy-
cline and rifampicin 600 mg daily for 6 months, together
with parenteral gentamicin 5 mg/kg/day for the first 14
days, with resolution of his symptoms and preservation of
his implant without revision surgery. Twelve months later he
has fully recovered with no signs of loosening of the joint
prosthesis on plain x-rays. The exposed laboratory personnel
were given doxycycline 100 mg twice daily for 21 days as
postexposure prophylaxis according to UK guidelines [3].
The patient made frequent visits to Thailand where he
had most recently stayed with a friend on his farm in Nakom
Pathom province from 11 December 2014 to 8 January 2015.
During that time, he helped deliver several parturient goats
and handled newly born kids and other products of
conception with his bare hands. He had not consumed
unpasteurised dairy products and had no contact with
cattle or buffaloes. Two farm workers had contempora-
neous fevers, only recognised to be due to brucellosis and
treated appropriately after our patient was diagnosed.
2.2. Literature review
PubMed and Scopus databases were searched using the
search string (((((((prosth*) OR replacement)) OR arthro-
plasty)) AND (((knee) OR hip) OR joint))) AND brucell*.
Studies were reviewed and data extracted by one author
(JL), with no restriction on date or language. Prosthetic
joint brucellosis was defined as either a) Brucella spp.
recovered from prosthetic joint synovial fluid culture OR b)
signs and symptoms consistent with PJI AND Brucella spp.
recovered from blood OR positive serology (standard
agglutination test [SAT] titre > 1:160 OR fourfold rise in
titre between acute and convalescent samples).
3. Results and discussion
The search returned 48 results in Scopus and 26 in
PubMed. After removal of duplicates, 47 remained. 18
Table 1 Summary of 24 patients with Brucella spp. prosthetic joint infection.
Reference Age Sex Country of
exposure
Traveller Occupation Prosthetic
implant
Time since
implantation
(months)
Brucella
SAT
titre
Radiographic
changes
Blood
cultures
positive
Joint
aspirate
culture
positive
Species Antibiotics
used
Antibiotic course
length (weeks)
Surgical
management
Follow up
(months)
Outcome
Jones et al.,
1983 [4]
54 M USA No Dairy
farmer
R THR 6 640 No loosening No No B. abortus Tetracycline
500 mg QID
Streptomycin
500 mg BID
6 e failed
therapy; followed
by 52 weeks;
Streptomycin first
6 only
One stage
revision once
medical
treatment
failed
24 Asymptomatic
Agarwal et al.,
1991 [5]
24 F Saudi
Arabia
No NR Bilateral TKR 2 2560 No loosening No Yes B. melitensis Rifampicin
300 mg BID
Co-
trimoxazole
980 mg BID
76 None 19 Pain free,
flexion 0e90
Orti et al., 1997
[6]
60 M Spain No “Works with
goats”
R TKR 14 160 No oosening No Yes B. melitensis Doxycycline
100 mg BID
Rifampicin
900 mg QD
Streptomycin
1 g QD
6
Streptomycin first
3 only
None 8 Symptom free
Navarro et al.,
1997 [7]
54 M Spain No Shepherd L internal
fixation of
femur
324 160 Loosening No NR B. melitensis Doxycycline
100 mg BID
Gentamicin
240 mg QD
34
Gentamicin first 1
only
Removal of
implant and
debridement
18 Asymptomatic
Malizos et al.,
1997 [8]
74 M Greece No Shepherd Bilateral TKR 5 160 No loosening Yes Yes B. melitensis Doxycycline
Streptomycin
Co-
trimoxazole
20
Streptomycin first
3 only
None 24 Asymptomatic
Ortega et al.,
2002 [9]
63 Spain No Cattle
owner
R THR 60 NR Loosening No NR B. melitensis Doxycycline
100 mg BID
Rifampicin
900 mg QD
Streptomycin
1 g QD
12
Streptomycin first
3 only
Two-stage
revision
6 “Satisfactory”
Weil et al., 2003
[10]
38 M Israel No Artist L THR 48 1600 Loosening NR No B. melitensis Doxycycline
200 mg QD
Rifampicin
600 mg QD
12
6 prior to surgery,
6 after
Two-stage
revision
12 Asymptomatic
Weil et al., 2003
[10]
61 M Israel No Retired R TKR 60 1600 Loosening NR No B. melitensis Doxycycline
200 mg QD
Rifampicin
600 mg QD
12
6 prior to surgery,
6 after
Two-stage
revision
12 Free of joint
pain
Weil et al., 2003
[10]
67 M Israel No Retired L TKR 168 1600 Loosening NR Yes B. melitensis Doxycycline
200 mg QD
Rifampicin
600 mg QD
12
6 prior to surgery,
6 after
Two-stage
revision
12 Free of joint
pain
Kasim et al.,
2004 [11]
47 F Lebanon No NR L THR 168 640 Loosening NR NR Brucella spp. Doxycycline
100 mg BID
Rifampicin
600 mg QD
20 One-stage
revision
48 Symptom free,
negative
Brucella titres
Cairo et al.,
2006 [12]
50 M Spain No NR L THR 0 320 No loosening Yes NR B. melitensis Doxycycline
100 mg BID
Streptomycin
1 g QD
104 Streptomycin
first 2 only
None 60 Well, negative
Brucella titres
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Cairo et al.,
2006 [12]
71 M Spain No Farmer R THR 36 NR Loosening No NR B. melitensis Doxycycline
100 mg BID
Rifampicin
600 mg QD
Streptomycin
750 mg QD
24
Streptomycin first
week only
Initially one
stage revision
(infection not
suspected);
later revision
THR after
failure of
medical
therapy
36 Well, negative
Brucella titres
Cairo et al.,
2006 [12]
74 F Spain No NR L tibial plate 180 80 NR NR NR B. melitensis Doxycycline
100 mg BID
Rifampicin
300 mg TID
Streptomycin
1 g QD
32
Doxycycline/
streptomycin first
week
Doxycycline/
rifampicin for
remainder
Initially bone
graft and
medical
therapy e
failed e then
two stage
revision
36 Satisfactory
range of
movement 0
e100 knee
Ruiz-Iban et al.,
2006 [13]
66 F Spain No Housewife THR 36 NR Loosening NR Yes B. abortus Doxycycline
200 mg QD
Rifampicin
900 mg QD
6 Two-stage
revision
66 Asymptomatic
Ruiz-Iban et al.,
2006 [13]
71 M Spain No Agricultural
worker
THR 28 640 No loosening NR No B. melitensis Doxycycline
200 mg QD
Rifampicin
900 mg QD
Streptomycin
200 mg QD
24 Streptomycin
first 6 only
Debridement 60 Asymptomatic
Marbach et al.,
2007 [14]
67 NR Sicily Yes NR Bilateral TKR 48 NR Loosening NR NR Brucella spp. Doxycycline
100 mg BID
Rifampicin
450 mg BID
12 Two-stage
revision
15 Good range of
movement
Tena et al.,
2007 [15]
56 M Spain No Farmer L THR 60 80 Loosening No Yes B. melitensis Doxycycline
100 mg BID
Rifampicin
900 mg QD
Streptomycin
1 g QD
8 Doxycycline/
streptomycin first
2 weeks
Doxycycline/
rifampicin for
remainder
Two-stage
revision
60 Asymptomatic,
good joint
function
Tassinari et al.,
2008 [16]
68 M Italy No NR R TKR 24 800 No loosening NR Yes B. melitensis Doxycycline
100 mg BID
Rifampicin
250 mg QD
8 None 12 Pain
disappeared,
no radiographic
changes
Dauty et al.,
2009 [17]
65 F Portugal Yes NR Bilateral TKR NR NR Loosening NR NR B. melitensis Doxycycline
200 mg QD
Rifampicin
900 mg QD
12 Two-stage
revision
120 Pain free,
walking
distance >
1 km
Erdogan et al.,
2010 [18]
63 F Turkey No NR R TKR 24 160 NR NR NR B. melitensis Doxycycline
200 mg QD
Rifampicin
600 mg QD
20
Initially 6 weeks,
followed by
revision TKR, then
16 weeks
One-stage
revision
36 Free of joint
pain, negative
serology
Nichols et al.,
2014 [19]
67 F Mexico No NR THR 24 NR Loosening NR NR B. abortus Doxycycline
Rifampicin
12 Two-stage
revision
No evidence of
infection
recurrence
Lowe et al.,
2015 [20]
NR NR India Yes NR THR NR NR NR NR Yes B. melitensis None e lost to
follow up
N/a None 0 Unknown
(continued on next page)
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448 J.M. Lewis et al.reports contained data on 23 patients with 26 Brucella-
related prosthetic joint infections; only 3 were in
returning travellers [4e21]. Table 1 summarises all 24
patients including: gender, country of exposure, type of
implant and time to symptom onset. In all cases Brucella
spp. were recovered from blood, synovial fluid or oper-
ative tissue sample. No diagnoses were made using
serology alone.
It is possible to draw several conclusions from these
cases; Brucella-related PJI is a late complication of joint
arthroplasty, with a median onset of 36 months after the
procedure. The diagnosis can be difficult to make: only 30%
(3/10) of reported blood cultures and 75% (9/12) of re-
ported joint aspiration samples cultured Brucella organ-
isms. Culture of intra-operative tissue samples probably
provides the best yield and confirmed the diagnosis in 15/24
cases; in these 15 cases joint aspiration was either not
carried out (12/15) or was culture-negative (3/15). In the
absence of radiological evidence of implant loosening,
medical management with antibiotics alone appears to be
effective in the first instance; of 24 patients with 27
infected prosthetic joints, 7 patients (with 9 infected
prosthetic joints) had radiologically well-seated implants
with no abscess or draining sinus. These patients underwent
antibiotic treatment alone for between 6 and 52 weeks,
with cure in 6/7 patients (8/9 joints) and failure of medical
therapy necessitating surgery in only one patient (one
joint). One patient with an infected joint that was radio-
logically well seated had a draining sinus, but was suc-
cessfully treated with debridement and adjuvant
antibiotics without explant of the prosthesis. However,
caution must be exercised in drawing firm conclusions on
optimal treatment from these data, given the small
numbers and the likelihood of selection bias inherent in
case reports.
Sixteen patients (with 17 infected joints) had features of
loosening on imaging; these all underwent either 1- or 2-
stage revision of their prosthesis alongside antibiotic ther-
apy, all with favourable outcome. One patient was lost to
follow up. Follow up was for a median of 24 months.
These cases also provide some guidance on appropriate
infection control measures when considering a diagnosis of
Brucella-related PJI. Infection of laboratory staff by
exposure to Brucella spp. is well recognised. Procedures
that generate aerosolized bacteria provide the highest risk
of exposure [22]. Synovial fluid from Brucella-infected
joints is likely to have a lower bacillary load than culture
bottles or plates and therefore exposure to synovial fluid
during joint aspiration or joint revision surgery probably
represents a lower risk exposure. Nevertheless, a case of
transmission during joint aspiration has been described, to
a radiology technician who assisted with injecting synovial
fluid from a Brucella-infected joint from a syringe into a
sample container [20]. Neither UK [3] nor US guidelines
[23] provide recommendations for risk assessment of po-
tential Brucella exposure outside the laboratory, or rec-
ommendations for PPE while performing joint aspiration or
surgery. We recommend that healthcare workers under-
taking aspiration of or surgery on joints in which Brucella
infection is suspected or confirmed are outfitted with PPE
including gown, visor and fit-tested FFP3 respirator or
equivalent.
Brucella prosthetic joint infection 449Brucellosis is not a diagnosis that would usually be
considered in a traveller returning from Thailand [24]. Two
cases acquired in Thailand have been mentioned in passing
in reviews of children [25] and adult [26] travellers
returning to North America and Europe respectively. Foci in
China, Mongolia and Central Eurasia are well recognised but
the range of other countries newly affected by brucellosis
continues to expand [2,27e30]. Human infections are
under-reported compared to the patchy knowledge of its
increasing incidence in livestock in South Asia [31]. A boy
acquired brucellosis from raw goat’s milk in Penang,
Malaysia in 2010 and a German visitor acquired brucellosis
in Myanmar from drinking lassi [32]. An outbreak of caprine
and human brucellosis in Ratchaburi Province in Thailand
was investigated in 2003 [33] and there have been sporadic
case reports and more recent reviews of emerging brucel-
losis endemicity in Thailand over the past decade [34e36].
As demonstrated by our patient, the highest risk to humans
in Thailand is exposure to parturient goats (B. melitensis)
but there is a separate risk of B. abortus transmission from
buffaloes. Diagnosis of illness in travellers can highlight the
presence of locally unrecognised infections, as shown by
this patient and his contacts.
4. Conclusion
In conclusion, we report the first detailed case report of
brucellosis in a traveller returning from Thailand. Clinicians
should consider brucellosis as well as the more commonly
encountered causes of fever in returnees from this area.
Brucellosis should be included in the list of possible causes
of an infected prosthetic joint in patients who have an
appropriate epidemiological risk and PPE, including fit-
tested masks, should be used by operators undertaking
joint aspiration or surgery in such cases. Though the small
number of cases identified in this review warrants caution
about drawing any firm conclusions regarding optimal
treatment, in the absence of implant loosening, treatment
with antibiotics may be appropriate in the first instance.
There are no specific strategies for avoidance of Brucella
spp. PJI beyond those needed by all travellers to prevent
brucellosis. These include the avoidance of unpasteurised
dairy products (including lassi and buffalo milk or cheese)
and animal contact (particularly in farms or abattoirs) in
endemic areas. Travellers (with or without prosthetic
joints) should be made aware of these risks as part of their
standard pre-travel assessment.
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